ALERT: Dexcom Share Server Failure!
UPDATE from the Dexcom Facebook Page, as of Monday, 2 December 2019, 5:25am PST:
At this time, the Dexcom Follow services have not yet been fully restored but we have seen significant improvement in system performance. Our teams continue to work around the clock on a resolution.
We are still investigating official root cause. However, we have determined that a server overload occurred due to an unexpected system issue that generated a massive backlog, which our system was unable to sufficiently handle.
While the outage is primarily impacting users of the follow app, there are some limited instances where users are experiencing issues logging into the Dexcom G5 and G6 apps. If users are experiencing login issues, they should swipe close the app, restart it and chose “login later” when prompted.
Additionally, in response to these issues please do not delete and reinstall the CGM app as it may not function properly. Keep the app open and installed.
As our teams work to solve this issue, we will continue to post regular updates here.
Diabetes Patients’ Blood-Sugar Data Aren’t Being Shared, as reported by Peter Loftus of The Wall Street Journal, 1 December 2019. DexCom device over the weekend stopped sending readings to smartphones, causing their “Share” service to fail.
Dexcom has only reported that they have been working around the clock to restore the functionality so very critical to users, particularly parents of young children with Type 1 diabetes. The servers failed on Saturday, 30 November, and as of 10pm, PST, 1 December 2019, have not been fully restored.
According to the Dexcom Facebook page, “12/1/2019, 2:10PM PST: As of right now, the Dexcom Follow services have not yet been fully restored. Additionally, you may be receiving a notice “server unavailable” in your G5 or G6 CGM app. In response to this notice, please do not delete and reinstall your CGM app as it may not function properly. Our teams continue to work on a resolution and we will continue to post updates here.”
Evopump: A Bandage-Like, Flexible “Patch” Insulin Pump was described by Mike Hoskins for DiabetesMine.com, 27 November 2019. Here’s the potential next evolution for insulin pumps: an ultra-thin Band-Aid like tubeless patch pump that sticks onto your skin, is flexible enough to bend and curve with your body, and has multiple reservoirs not only for insulin but for other medications like glucagon to boost blood sugars when necessary.
Evopump, under development by Boston-area medical device startup Cam Med (founded in 2014) which specializes in microfluidic-based drug delivery, and won an innovation award from the T1D Exchange in 2017 and then partnered with JDRF a year later to create this future multi-reservoir flexible patch pump.
“With the Evopump’s low profile, flexible form factor and the ability to deliver more that one medication, we are poised to not evolve the on-body insulin delivery market, but to revolutionize that market,” says Cam Med’s Chief Commercial Officer Richard Spector, who lives with type 1 diabetes himself and formerly worked at Insulet.
Its unique features:
- Flat, Ultra-Thin, and Soft: The insulin-holding part of the device is rectangular and thin like a bandage, less than one centimeter in height.
- Fill and Stick On: A user will fill up the Evopump with insulin (up to 300 units) and then peel off the back adhesive, before sticking it onto the body. It has a circular spring-loaded applicator, that the user twists to remove and dispose of, so only the thin patch pump remains on the body.
- Driven by Currents: The Evopump is driven by an electro-chemical reaction — electrical currents generating gas bubbles inside, allowing for a precise amount of medication (insulin / glucagon / etc.) to be delivered through the structural membrane via the cannula underneath the skin.
- Multi-Reservoir: Evopump contains an array of tiny reservoirs with small electro-chemical actuators at each, and a microfluidic tubing network connecting the reservoirs to a soft, subcutaneous cannula.
- Wireless BLE Tech: The Evopump uses built-in Bluetooth Low Energy (BLE) tech to beam data directly to either a smartphone app or a separate handheld retriever.
- Access and Affordability? The unique design of the Evopump enables it to be manufactured at a fraction of the cost of existing pumps, enabling Cam Med to mass produce the Evopump for what it currently costs to create a traditional insulin pen.
Tandem t:Sport is coming to Europe!!!
The company plans to launch t:sport Insulin Delivery System, its next-generation hardware platform, in 2020 or 2021. Management plans to submit the pump for 510(k) clearance as an ultimate controller enabled pump in the summer of 2020. Tandem Diabetes’ first t:sport cartridge line is currently in manufacturing stage and the company plans to submit it for CE Mark in 2020.